Gaffey Ann C, Zhang Jason, Lee Major K, Roses Robert, Jackson Benjamin M, Quatromoni Jon G
Division of Vascular and Endovascular Surgery, Department of Surgery, University of California, San Diego, La Jolla, CA.
Division of Vascular Surgery and Endovascular Therapy, University of Pennsylvania Health System, Philadelphia, PA.
J Vasc Surg Cases Innov Tech. 2022 Apr 22;8(2):294-297. doi: 10.1016/j.jvscit.2022.04.001. eCollection 2022 Jun.
Improvements in chemoradiotherapy have rendered complex pancreatic cancers involving the portal vein (PV) amenable to resection. PV reconstruction (PVR) is an essential component. Various conduits have been proposed; however, the optimal choice remains unknown. Fourteen patients underwent PVR with a cadaveric descending thoracic aortic homograft from 2014 to 2020. The primary diagnosis was pancreatic cancer. The splenic vein was ligated in seven patients (50%). The 30-day and 3-, 12-, and 24-month primary patency rates were 100%, 86%, 76%, and 76%, respectively. We found a cadaveric descending thoracic aortic homograft is an excellent conduit for PVR, given the optimal size, rapidly availability, favorable risk profile, and absence of harvest site complications.
放化疗的进展使得累及门静脉（PV）的复杂胰腺癌适合进行切除术。门静脉重建（PVR）是其重要组成部分。已提出了各种导管；然而，最佳选择仍不明确。2014年至2020年期间，14例患者接受了使用尸体降主动脉同种异体移植物的门静脉重建。主要诊断为胰腺癌。7例患者（50%）结扎了脾静脉。30天以及3个月、12个月和24个月的初次通畅率分别为100%、86%、76%和76%。鉴于尺寸合适、可快速获取、风险特征良好且无供体部位并发症，我们发现尸体降主动脉同种异体移植物是门静脉重建的理想导管。
